cc-401

CC-401 is a second-generation ATP-competitive anthrapyrazolone c-Jun N-terminal kinase (JNK) inhibitor with potential antineoplastic activity. It competitively binds the ATP binding site of JNK isoforms (JNK1/2/3), resulting in inhibition of the phosphorylation of the N-terminal activation domain of transcription factor c-Jun and decreased transcription activity. This leads to reduced cellular proliferation and other downstream effects relevant to cancer and inflammatory diseases. CC-401 has been investigated in clinical trials for refractory acute myelogenous leukemia but is not currently being pursued for further development by its originator[2][7][9].

Other names

3-[3-[2-(piperidin-1-yl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)-1H-indazole3-[3-(2-piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole hydrochloride (for hydrochloride salt)NOE38V901W (UNII)DTXSID40192650[2][7][9]